Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAR 441566

Next Previous
X
Search
Drug Profile

SAR 441566

Alternative Names: SAR-441566

Latest Information Update: 13 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease; Psoriasis; Rheumatoid arthritis
  • No development reported Inflammation

Most Recent Events

  • 10 Dec 2024 Phase-II clinical trials in Crohn's disease (Treatment-experienced) in USA, Australia (PO) (NCT06637631) (EUCT-2024-512633-32-00)
  • 15 Oct 2024 Sanofi plans a phase II SPECIFI-CD trial for Crohn's disease (Treatment-experienced) (PO) in November 2024 (NCT06637631)
  • 28 May 2024 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in France (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top